Search Results

Tivantinib (ARQ 197) Evaluation Sample  | 99.66%

APEXBIO TECHNOLOGY LLC

C-Met inhibitor,non-ATP-competitive Tyrosine Kinase|c-MET

More Information Supplier Page

×

Tivantinib (ARQ 197)

Tivantinib (ARQ 197) 5mg  | 99.66%

APEXBIO TECHNOLOGY LLC

C-Met inhibitor,non-ATP-competitive Tyrosine Kinase|c-MET

More Information Supplier Page

×

Tivantinib (ARQ 197)

Tivantinib (ARQ 197) 20mg  | 99.66%

APEXBIO TECHNOLOGY LLC

C-Met inhibitor,non-ATP-competitive Tyrosine Kinase|c-MET

More Information Supplier Page

×

Tivantinib (ARQ 197)

Tivantinib (ARQ 197) 100mg  | 99.66%

APEXBIO TECHNOLOGY LLC

C-Met inhibitor,non-ATP-competitive Tyrosine Kinase|c-MET

More Information Supplier Page

×

Tivantinib (ARQ 197)

LDN-193189 50mg  | 98.98%

APEXBIO TECHNOLOGY LLC

ALK inhibitor,potent and selective TGF-β / Smad Signaling|SMAD

More Information Supplier Page

×

LDN-193189

LDN-193189 10mg  | 98.98%

APEXBIO TECHNOLOGY LLC

ALK inhibitor,potent and selective TGF-β / Smad Signaling|SMAD

More Information Supplier Page

×

LDN-193189

LDN-193189 5mg  | 98.98%

APEXBIO TECHNOLOGY LLC

ALK inhibitor,potent and selective TGF-β / Smad Signaling|SMAD

More Information Supplier Page

×

LDN-193189

WP1130 100mg  | 99.2%

APEXBIO TECHNOLOGY LLC

Deubiquitinase (DUB) inhibitor, Cell permeable Ubiquitination/ Proteasome|DUB

More Information Supplier Page

×

WP1130

WP1130 50mg  | 99.2%

APEXBIO TECHNOLOGY LLC

Deubiquitinase (DUB) inhibitor, Cell permeable Ubiquitination/ Proteasome|DUB

More Information Supplier Page

×

WP1130

Neratinib (HKI-272) 25mg  | 99.81%

APEXBIO TECHNOLOGY LLC

HER2/EGFR inhibitor,potent and irreversible JAK/STAT Signaling|EGFR

More Information Supplier Page

×

Neratinib (HKI-272)